Home » Stocks » Gritstone Oncology

Gritstone Oncology, Inc. (GRTS)

Stock Price: $2.91 USD -0.03 (-1.02%)
Updated Oct 27, 2020 1:15 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 109.85M
Revenue (ttm) 3.62M
Net Income (ttm) -107.33M
Shares Out 37.75M
EPS (ttm) -2.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $2.91
Previous Close $2.94
Change ($) -0.03
Change (%) -1.02%
Day's Open 2.91
Day's Range 2.90 - 2.98
Day's Volume 43,796
52-Week Range 2.60 - 12.96

More Stats

Market Cap 109.85M
Enterprise Value 44.43M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 37.75M
Float 24.26M
EPS (basic) -2.94
EPS (diluted) -2.95
FCF / Share -2.82
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.34M
Short Ratio 5.83
Short % of Float 9.64%
Beta 1.12
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 30.36
PB Ratio 1.18
Revenue 3.62M
Operating Income -109.53M
Net Income -107.33M
Free Cash Flow -105.15M
Net Cash 65.42M
Net Cash / Share 1.73
Gross Margin -2,170.56%
Operating Margin -3,027.22%
Profit Margin -2,966.40%
FCF Margin -2,906.25%
ROA -36.62%
ROE -77.05%
ROIC -101.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 3
Overweight 1
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(303.78% upside)
Current: $2.91
Target: 11.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth267.73%---
Gross Profit4.371.19--
Operating Income-97.94-65.58-41.76-18.98
Net Income-94.43-64.78-41.38-18.75
Shares Outstanding33.558.922.001.67
Earnings Per Share-2.81-7.26-20.70-11.21
Operating Cash Flow-85.01-38.16-34.97-15.29
Capital Expenditures-16.17-5.66-11.49-6.98
Free Cash Flow-101-43.83-46.46-22.28
Cash & Equivalents12815385.9537.51
Total Debt23.4910.4910.52-
Net Cash / Debt10414375.4337.51
Book Value13414997.2841.69
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Gritstone Oncology, Inc.
Country United States
Employees 176
CEO Andrew R. Allen

Stock Information

Ticker Symbol GRTS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GRTS
IPO Date September 28, 2018


Gritstone Oncology, an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.